The breast cancer treatment landscape is changing, and the optimal adjuvant endocrine therapy for premenopausal women with hormone receptor (HR)-positive breast cancer is uncertain.
The results of the CHAARTED trial, which looked at whether the addition of upfront chemotherapy to hormonal therapy improved overall survival in patients with hormone-sensitive metastatic prostate cancer, were presented at the ASCO Annual Meeting.
At the ASCO/AACR Joint Session on Inflammatory Cells and Cancer, Dr. Andrew Dannenberg from Weill Cornell Medical College, gave a fascinating lecture titled “Stromal Inflammation and Solid Tumors.”
Multiple abstracts on melanoma and skin cancer were reviewed at the ASCO Annual Meeting, with a focus on new treatment approaches in non-melanoma skin cancers, particularly basal cell carcinoma and Merkel cell carcinoma.
On Monday during ASCO, Dr. Axel Hauschild reviewed the role of intralesional therapy in melanoma in a sub-session of the melanoma abstract review talk entitled “Evolving Utility of Intralesional Therapy for Melanoma.”
When treating patients, we often ask ourselves how the results of the tests we order will potentially change our management of the patient, or change the way we think about our patient’s disease, or offer information that will enhance our treatment approach.
In his address, Dr. Clifford Hudis proposed the following solutions for achieving social justice in cancer care: creating more private and public resources, addressing disparities in cancer risk and in access to high-quality care, defining “value” in cancer care, and harnessing the new power of information technology.
With cancer care costs rising rapidly there is increased pressure to search for value in how we care for our patients.
The cost of healthcare is spiraling out of control in the United States, and compared with other countries we don’t even have better health indices to show for it. We currently spend $2.8 trillion annually on healthcare, and this is predicted to increase greatly in the coming years.
One of the most fascinating sessions I attended so far here at ASCO was on payment reform. As a faculty member of a cancer center at a state university, I generally consider myself lucky that I can remain quite sheltered from the financial side of oncology clinical care.